Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright's target price points to a potential upside of 216.83% from the company's current price.
Separately, William Blair restated an "outperform" rating on shares of Barinthus Biotherapeutics in a research note on Monday, January 8th.
Check Out Our Latest Research Report on BRNS
Barinthus Biotherapeutics Stock Down 6.8 %
NASDAQ:BRNS traded down $0.19 during mid-day trading on Friday, hitting $2.53. 3,440 shares of the stock traded hands, compared to its average volume of 19,747. The stock has a market cap of $98.27 million, a PE ratio of -1.31 and a beta of -0.52. Barinthus Biotherapeutics has a 52 week low of $1.64 and a 52 week high of $5.10. The stock has a 50 day moving average price of $2.69.
Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.10. Research analysts predict that Barinthus Biotherapeutics will post -2.6 EPS for the current fiscal year.
About Barinthus Biotherapeutics
(
Get Free Report)
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
Further Reading
Before you consider Barinthus Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Barinthus Biotherapeutics wasn't on the list.
While Barinthus Biotherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
